LIFETECH SCI (01302.HK) announced that on September 16, 2019, via Shenzhen Yunma Biotech (a joint venture by LIFETECH SCI and Sorrento Pharmaceuticals), the company reached a joint laboratory cooperation agreement with Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences (SIAT). According to the agreement, Shenzhen Yunma and the Institute of Brain Cognition and Brain Diseases of SIAT have established the Joint Laboratory of the SIAT-Shenzhen Yunma Biotechnology Co., Ltd. to conduct cannabinoid research on treating brain diseases, especially for research of water-soluble CBD treating cognitive disorders such as epilepsy, autism, phobia, Parkinson’s disease, sleep disorders, etc., and also such research date will be served for future commercialization plan. At the same time, based on their respective advantages, the two parties will apply for the science and technology subsidies of all levels of government for the joint laboratory.
At present, the global scientific research and clinical practice of cannabinoids (including CBD) products have initially shown its huge commercial value. The establishment of the joint laboratory will benefit the Shenzhen Yunma to expedite the research on the application of cannabinoids in relevant fields. As of September 17, 2019, the Institute of Brain Cognition and Brain Disease has successfully developed animal models of genetic mutations in cranial nerve diseases. Both parties have conducted relevant research in accordance with definitive detailed experimental protocols. The first phase focuses on water-soluble CBD to improve the social activity, stereotypic behavior and sleep disorders of adult mice as autism model; the second phase focuses on the preclinical research and treatment of water-soluble CBD on children with autism and exploratory research on the treatment of Parkinson’s disease. Relevant experimental data will help Scintilla Health, Inc. (The US joint venture company established by the company and Sorrento Pharmaceuticals) to apply for the FDA approval for marketing CBD medicines.
As of September 17, 2019, the company and Sorrento Pharmaceuticals have made relevant progress on the application of water-soluble CBD. via the mouse model, it has been verified that the bioavailability of water-soluble CBD medicines is almost 4 times larger than its fat-soluble CBD counterparts. The concentration of CBD in the blood can reach its peak faster. The results preliminarily demonstrate the technical advantages of water-soluble technology in medical, edible and consumer goods industry. The joint venture company established by the two parties will further expand its business in relevant fields according to the business layout.
Read more about Water-Soluble CBD Research in China, see: